Abuse-resistant opioid maker hires pharma veteran as CEO, raises $14 million

8:07 am by | 0 Comments

deal, agreementA drugmaker specializing in extended release, abuse-resistant drug delivery for opioids has raised more than $14 million in series B financing to advance its lead products through clinical trials. It has also hired a pharmaceutical veteran as its CEO.

Bob Radie has joined Malvern, Pennsylvania-based Egalet as president and CEO. Radie has nearly 30 years of experience in the pharmaceutical and biotechnology industries, and previously worked as CEO of Topaz Pharmaceuticals, acquired by Sanofi Pasteur last year. He also served as CEO of TransMolecular Inc., a biotechnology company focused on novel cancer diagnostic and treatment products, later acquired by Morphotek. He has also worked for Eli Lilly, according to a company statement.

The company relied on existing investors for the financing round, including Atlas Venture, Omega Funds, Sunstone Capital and Index Ventures.

Egalet’s erosion technology means the drug is gradually absorbed and is part of an effort by some drugmakers to address the costly problem of prescription drug abuse.


Copyright 2015 MedCity News. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Stephanie Baum

By Stephanie Baum

Stephanie Baum is the East Coast Innovation Reporter for MedCityNews.com. She enjoys covering healthcare startups across health IT, drug development and medical devices and innovations deployed to improve medical care. She graduated from Franklin & Marshall College in Pennsylvania and has worked across radio, print and video. She's written for The Christian Science Monitor, Dow Jones & Co. and United Business Media.
Visit website | More posts by Author